Andrew Left's Citron Research (http://www.citronresearch.com/) (formally known as Stocklemon.com) seeks to expose companies whose management is in some way misleading investors. Left digs into SEC filings, financials, management histories and other data to uncover such situations, and he is usually short the stocks he writes about. Mr. Left has been publishing for 7 years and has created a track record that is unrivaled in short selling. Mr. Left has been cited in Barron's, Wall St Journal, CNBC and other major publications repeatedly for his work. Mr. Left was also an invited speaker at the reknown Master Investor Conference.
Visit: Citron Research (http://www.citronresearch.com/)
BQ started his career more than a decade ago as a trading algorithm developer and later became a research analyst. He currently manages a fund of family and friends, and is pursuing an entrepreneurial opportunity in the financial domain. Found the hard way that investing tended to return healthier and sustainable returns than day trading. He's an Electronics and Communications engineer, holds an MBA in Finance and writes mostly about Technology and Telecom companies.
I am a licensed attorney with a B.S. in Economics from the Wharton School.
I look for opportunities to invest in growing companies, especially if I feel that they are currently misunderstood in one or more aspects. Much of the PTI portfolio is made up of high-growth, high-volatility equities, both domestic and international. While such investments will often test one's mettle in the short term, I believe that these companies offer significant potential for outsized growth when viewed with a long-term perspective.
Have the courage of your convictions, the humility to admit that you were wrong, and the wisdom to tell the difference between the two.
I have been successfully and exclusively investing in Biotech for 15 years. I employ my scientific training and business experience to gain an unfair advantage on my stock selections. Over the years, I have developed a very narrow investment thesis focusing on small-mid cap biotechs developing therapeutics to address serious medical conditions. I run a small IT company and co-manage the biotech holdings of a small hedge fund.
Adam Hartung has more than 30 years of practical experience developing and implementing successful strategies to take advantage of emerging technologies and new business models.
He is currently CEO of Spark Partners, Content Laboratory, Inc. and Soparfilm Energy Corporation. Additionally, Adam Chairs the Audit Committee on the Board of Directors for Six Dimensions Global (SIXD,) and has been on the Board at several privately held companies. Adam provides board advisory services via the National Association of Corporate Directors (NACD) where he is a Fellow and regular speaker on risk management across multiple industries.
Adam is the No. 1 Leadership columnist for Forbes.com with over 3 million readers, and quarterly Leadership columnist for CIO Magazine. He has been featured in dozens of journals, including Adweek, Washington Times and BBC television.
Adam received his MBA from the Harvard Business School with Distinction and continues to travel the globe leading risk management workshops as well as conference and management meeeting keynotes.
Special situations value investor. Cap Intro appreciated.
15 year investing experience, mostly on buy-side. Hope to provide actionable ideas with attractive upside/downside with non-fundamental reasons for mispricing. Typically smaller cap names where inefficiencies are more likely to exist.
Richard Zeits is an Oil & Gas industry analyst and consultant. His background includes fourteen years as Energy industry-focused investment banker, portfolio manager and senior investment analyst with bulge bracket firms in New York. Zeits Energy Analytics use elaborate proprietary analytics and data bases to provide in-depth industry research, market intelligence, and forecasting.
As a natural resources industry expert and with a passion for investing, I conduct in-depth research to generate valuation-based, actionable investment ideas for the member of The Natural Resources Hub (TNRH), a popular Seeking Alpha Marketplace service which also features top-performing model portfolios and a lively Chat Room.
With a Ph.D. in geosciences, I have worked for decades in research, oil and gas industry, and industry data management. I have been managing family investment accounts through bull and bear markets with great returns. My hands-on industry working experience helps me in uncovering opportunities in the oil and gas, mineral resources, and other areas.
I focus on identifying deep values and undervalued moated businesses with an asymmetrical risk-reward profile. My investing style is contrarian and mostly long.
Find some abridged samples of my specific, valuation-based, actionable investing ideas here: http://seekingalpha.com/author/laurentian-research-lab/articles#regular_articles
Or fully experience TNRH by signing up here: https://seekingalpha.com/author/laurentian-research/research.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
President of Almington Capital - Merchant Bankers.
Investing in publicly traded securities, private equity, real estate, venture capital.
Taking advantage of deep value opportunities, growth opportunities, and special situations across a range of asset classes and industries.
Value & Momentum Breakouts. If targeting 5% weekly or monthly returns is more appealing to you than chasing 5% annually, please join me as I publish my latest findings in weekly and monthly articles! During my more than 25 years of investing I got bored with low annual returns and began looking to harness well documented financial anomalies for excess risk adjusted returns. I leverage forensic analysis and the latest academic financial models to identify profitable irregularities in fundamental and momentum characteristics. I am a finance PhD and MBA who is always looking for new investments and profitable opportunities in an ever changing market. I am also a certified fraud examiner and investment adviser who thoroughly enjoys testing new financial theories.
Our TipRank profile: https://www.tipranks.com/bloggers/hfir
HFI Research specializes in contrarian investment analysis. We help you to find clarity in a world of uncertainty. We take contrarian thinking very seriously and believe that the only way to obtain a real edge in the market is to possess a contrarian investment thesis. We share our investment analysis with premium subscribers through daily and weekly reports.
HFI Research Premium currently includes:
What Changed This Week - Our flagship weekly report that covers macro themes, energy equities, and other stock ideas we analyzed.
What Research Reports We Read This Week - Our weekly analysis of the research reports we read that week.
Daily Natural Gas Fundamentals - Our flagship daily natural gas fundamentals and weather update report (also offered by HFI Research Natural Gas).
Daily Pain - Our premium daily that discusses the ever changing market dynamic the team currently sees. Pain Capital writes this report for us.
Individual Stock Analysis - Subscriber only stock analysis and updates.
For more info, please message us.
Intrepid Leader at an RIA. My firm and I simplify the lives of busy clients by providing ongoing financial planning and asset management. this is done by providing our clients customized, ongoing comprehensive financial planning, and customized investment advisory services tailored to the clients' needs. As a fiduciary, we have a legal obligation to put the needs and interests of our clients above our own. Specialties: fee based comprehensive financial planning, retirement planning, life insurance and protection planning.
Ian worked for Kerrisdale, a New York activist hedge fund, for three years, before moving to Latin America to pursue entrepreneurial opportunities there. His Ian's Insider Corner service provides live chat, model portfolios, full access and updates to his "IMF" portfolio, along with a weekly newsletter which expands on these topics.
Ian is also an associate analyst for Value Investor's Edge. VIE is a top-ranked deep value research service featuring exclusive work from J Mintzmyer, James Catlin, and Ian Bezek.
I use Seeking Alpha to publish my analysis and offer my perspective to other investors.
I enjoy learning from my fellow writers as well! If you live in San Francisco or in the Bay Area, feel free to send me a message to coordinate meetups to discuss stock investing, finance, etc.
You can connect with me on Twitter: https://twitter.com/RonaldLiu3
Hi I'm Chaim Siegel. I've run Elazar since inception in 2004.
In my career working at Morgan Stanley, SAC, JLF and my own firm I've always been known to be a stock picker with the ability to uncover the big calls.
I don't think it's so so complex. It's a process. I speak to companies, understand how businesses work and how different scenarios affect the earnings.
Our earnings numbers have been included in the official street numbers and we've appeared in the Wall Street Journal and MarketWatch.
We have a service here on Seeking Alpha, "Nail Tech Earnings" where we work for you to find the best tech stocks with the most upside potential.
PS We think we are going into an absolute multi-year tech boom which is why we're doing this service for you here. Not bubble, tech boom.
We speak to a ton of company managements, show you all our work, take your requests, have great interaction through the day on chat, give you our models before they hit the street, and tell you which stocks can make you the most money.
If you have any questions on anything what-so-ever, please let me know.
Wishing you happy and profitable investing.
Bespoke Investment Group provides some of the most original content and intuitive thinking on the Street. Founded by Paul Hickey and Justin Walters, formerly of Birinyi Associates and creators of the acclaimed TickerSense blog, Bespoke offers multiple products that allow anyone, from institutions to the most modest investor, to gain the data and knowledge necessary to make intelligent and profitable investment decisions. Along with running their Think B.I.G. finance blog, Bespoke provides timely investment ideas through its Bespoke Premium (http://bespokepremium.com/) subscription service and also manages money (http://bespokepremium.com/mm) for high net worth individuals.
Visit: Bespoke Investment Group (http://bespokeinvest.com/)
I search for companies that are undervalued due to fear that have strong fundamentals in order to buy long, and companies that are overvalued due to greed that have weaknesses such as poor free cash flow or an unviable business model in order to short them. As Warren Buffet recommends: buy fear and sell greed. When I find potential candidates, I research the daylights out of them and only choose the best opportunities. To give you an idea of some the stocks I’ve focused on, in the past I successfully shorted Twitter, GoPro, Garmin, TrueCar, FCX, Wayfair, Pandora and Transocean, and was successfully long Cisco, Expedia, Goodyear Tire, Facebook, Apple, Celgene and Delta. Many of those are no longer good shorts or longs. My current favorite long stock is Iconix (ICON). I was previously a consultant for executives at companies such as Fidelity Investments and Google, including the Vice-president of Sales at Google. Prior to that I owned and operated two retail stores that I sold, and before that I was a journalist. I’ve been investing for 22 years in stocks, bonds, commodities and options. I spend a lot of my free time researching investments and donate half of the gains to charity.
Former analyst at a long/short value-oriented hedge fund now managing a fund of my own. I believe it's important to put your money where your mouth is when investing, so I will generally write only about stocks that I own or am likely to purchase in the near future. For exclusive ideas and real-time access to my full portfolio, consider subscribing to my service, "Beating the Market with SoF".
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
BIO: Vincent Tizono is a financial analyst and private speculator. He graduated summa cum laude with a Bachelor of Science from Rocky Mountain College. He's a former Edward Jones Financial Advisor who worked at Edward Jones Headquarters in St. Louis, Missouri, handling multiple offices in transition. The cumulative assets under management for the 11 advisor team totaled over $400 million. Furthermore, Vincent was apart of the FACD program at Edward Jones, which only 1 in 500 applicants are accepted into.
I have a unique talent for finding high-quality speculations and catalyst plays in the biotech space. My last six speculations were ZSAN, FLXN, CPRX, VSTM, OCUL, and AUPH. I wrote articles outlining each of these opportunities; except for ZSAN and FLXN which were just blog posts stating that they were currently worth buying as speculations. All four articles and the two blog posts can be found under my profile.
ZSAN--22% in 5 days (the write up is in my Sep 30th Biotech Brief)
FLXN--21% in 65 days
CPRX--26% in 5 days
VSTM--24% in 3 days
OCUL--14% in 5 days
AUPH--42% in 6 days
--Returns have been calculated by assuming that a position was taken on the open of the day that the piece was published and sold on the close of the day that it hit my stated price target or, in the absence of that, the day before the data readout.
The results of my Long-term oriented articles:
CARA: The stock ran up 86% between the time of my first article and my second article. Also, I explained in my second article that I thought it was smart to lock in profits and thus reduced my position to only 25% of my original position.
AIMT: The stock is currently up a little over 69% since my first article.
GWPH: -- I didn’t suggest buying at these levels but rather I explained why I am still holding long even though I, at that point, was up 188% (I included a pic of my brokerage account since 188% is such a stellar return and thus a large claim)
TTNP: I articulated why the equity would struggle, and currently the stock is down a little over 50% since my article.
PLX: The stock is down since I wrote about it, but this is the type of little stock that you either make multiples of your money or it will go to zero. Thus, size your position accordingly and check back in a couple of years.
(Long-term is often seen as 5 years + but I focus on the fast-moving and highly volatile industry of small-cap biotech, so I consider long-term as 1 year or more)
My Style: I look for compelling speculations in the small/mid-cap space of the biotech industry. Each speculation has its own nuances and idiosyncratic risks that are associated with it. However, generally speaking, my speculating focuses on finding windows in time when probability favors appreciation, there’s solid visibility on the risks and possible outcomes, and a high reward to risk ratio is present. Furthermore, equity markets manipulate the emotional weaknesses of speculators. Thus, my entries, exists, and sizing of positions are decided on in a systematic fashion. Lastly, I believe that sound bankroll/risk management is the key to profitable speculation. Proper bankroll/risk management is what will allow you to overcome the randomness that is inherent in security speculation by allowing you to handle drawdowns from a negative sequence of returns.
Wisdom: “No man so wise that he may not easily err if he takes no other counsel than his own. He that is taught only by himself has a fool for a master”-Ben Johnson
"There is nothing so disastrous as a rational investment policy in an irrational world"-John Maynard Keynes
"Amateurs care about how much they can make, but professionals care about how much they can lose"
To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 6 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
Investor/Trader in biotech and tech sectors for 10 years. Founder & Editor of ROTY (Runners of the Year), a strategy and now Marketplace Service focused on discovering opportunities to achieve high % gains within a year´s time frame.
Importantly, I often highlight risk management and entry/exit strategies, as I believe they represent areas that are often neglected but materially important for readers to understand and apply if they want to be profitable long term.